This playful title is not only to rhyme with my actual one but also to convey a look back as well as forward, as this marks the first month after completing my initial 5‐year term as Editor‐in‐Chief. I am buoyed (and “relieved”) to have been given the privilege to continue and thank FASEB for wanting me to do so.

We are now publishing more than twice the volume of papers as when I took over (451 in 2015, vs. 1087 in 2020), and there is no sense of reduced quality. This is due to the dedicated work of the Associate Editors and the Editorial Board, as well as the increasing reputation of the Journal—these two intertwined as to causation. Despite the increased volume of submissions, our average time to first decision remains at a most respectable 21.6 days.

During the past 5 years, I made changes at both levels, with due appreciation to those leaving. All the new Associate Editors and Editorial Board Members have rallied to the cause of elevating the Journal's visibility, to fortify our coverage of key fields and to bolster our attraction of manuscripts in new ones.

One endeavor of which I was especially proud during my first term was the introduction of two focal series of Reviews. The first, led by Editorial Board Member Joel Buxbaum (Scripps Research Institute) was a series of articles on Alzheimer's disease that offered different concepts than the prevailing hypothesis. A second, now in progress, has been organized by Nina Stachenfeld (Yale School of Medicine) on the factor of sex as a variable in biomedical research. Other such series are being planned.

The coronavirus pandemic led me to introduce a policy in April 2020, whereby an Associate Editor or I could accept a relevant paper in our Hypotheses, Perspective, or Review categories (but not in the Research Article category) without further review if this were deemed appropriate. This fast‐track policy resulted in 11 publications, and several more coronavirus‐related submissions were published following standard review.

Our new publishing relationship with John Wiley & Sons has given us an experienced partner that has welcomed us and with which we are working catalytically, especially in publishing and marketing dimensions, where the partnership is offering new opportunities arising from what each of us brings. A new strategic plan for The FASEB Journal is being developed at the time of this editorial, and while no draconian changes are envisioned, I am optimistic that we will find ways to further enhance the Journal's presence and penetration.

If anyone concludes that I have been successful the past 5 years, it is not only because of the Associate Editors and Editorial Board, but also because of a very smart and dedicated team in the editorial office, led by Mary Kiorpes Hayden (Managing Editor), M.R. Carey (Production Coordinator), and Srilaxmi Bhargava (Peer Review Assistant). Susan DeCourcey (Director of Publishing and Society Management Services) leads the entire operation, and Karen King (Interim Director of Publications) has been a key part of the team.

As everyone knows, publishing is undergoing changes, in all fields of science and the humanities. The FASEB Journal, and FASEB, are aware of them and will endeavor to lead, not follow. The Journal is also ever cognizant that while it serves a broad biomedical readership, it also represents FASEB's 29 constituent member societies. I think this gives the Journal and FASEB the power and fortitude to lead the cause of basic and translational biomedical research, not only in publishing but also in the advocacy of science as the never‐wavering path to the truth.

这个有趣的标题不仅与我的实际名字押韵，而且还传达了向前和向后的回顾，因为这标志着我最初担任总编辑的五年任期结束后的第一个月。我被赋予（并“解除”）特权，让我继续前进，并感谢FASEB希望我这样做。

现在，我发表论文的数量是我上任时的两倍（2015年为451，而2020年为1087），并且没有质量下降的感觉。这是由于副编辑和编辑委员会的辛勤工作，以及《华尔街日报》声誉的提高-这两个因果关系相互交织。尽管提交的数量有所增加，但我们做出决定的平均时间仍是最可观的21.6天。

在过去的五年中，我对这两个级别进行了更改，并对那些离开的人员表示赞赏。所有新的副编辑和编辑委员会成员都团结起来，以提高《期刊》的知名度，加强我们对关键领域的报道并增强我们对新手稿的吸引力。

在我上任第一学期时，我特别感到自豪的一项工作就是引入了两个重点的评论系列。由编辑委员会成员乔尔·布克斯鲍姆（Scripps Research Institute）领导的第一篇文章是有关阿尔茨海默氏病的一系列文章，提供的概念与普遍假设不同。Nina Stachenfeld（耶鲁大学医学院）已经组织了第二个研究，该研究将性别因素作为生物医学研究中的变量。其他此类系列正在计划中。

冠状病毒大流行使我在2020年4月推出了一项政策，根据该政策，副编辑或我可以接受“假设”，“观点”或“评论”类别（但不属于“研究文章”类别）中的相关论文，如果认为合适，则无需进一步审核。这项快速的政策导致发表了11篇文章，并在标准审查后发表了更多与冠状病毒相关的论文。

我们与约翰·威利父子公司（John Wiley＆Sons）的新出版关系为我们提供了一个经验丰富的合作伙伴，该合作伙伴一直欢迎我们，并且我们正在与之紧密合作，特别是在出版和营销方面，该合作伙伴关系为我们每个人带来了新的机遇。在本社论发表之时，正在为《 FASEB杂志》制定一项新的战略计划，尽管未预见到任何严峻的变化，但我感到乐观的是，我们将找到进一步提高该杂志的影响力和渗透率的方法。

如果有人断定我在过去五年中取得了成功，这不仅是因为副编辑兼编辑委员会，而且还因为编辑室的一个非常聪明和敬业的团队，由Mary Kiorpes Hayden（总经理）领导，MR Carey（生产协调员）和Srilaxmi Bhargava（同行评审助理）。Susan DeCourcey（出版和社会管理服务总监）领导整个业务流程，Karen King（出版物临时总监）一直是团队的关键部分。

众所周知，出版在科学和人文科学的各个领域都在发生变化。FASEB期刊和FASEB均已意识到它们，并将努力领导而不是跟随。《华尔街日报》也一直认识到，尽管它为广泛的生物医学读者服务，但它也代表了FASEB的29个成员协会。我认为，这使《华尔街日报》和FASEB拥有领导基础和转化性生物医学研究事业的力量和毅力，不仅在出版方面，而且在倡导科学作为通往真理的永不动摇的道路上。